Efficacy and safety of intravitreal injection of amikacin for endophthalmitis: a systematic review

IF 0.4 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Zichao Ji, Yue-Ping Xie, Xin Wang, Guang-Yao Li, Chao Zhang
{"title":"Efficacy and safety of intravitreal injection of amikacin for endophthalmitis: a systematic review","authors":"Zichao Ji, Yue-Ping Xie, Xin Wang, Guang-Yao Li, Chao Zhang","doi":"10.32383/appdr/163452","DOIUrl":null,"url":null,"abstract":"The aim of this study was to evaluate the efficacy and safety of intravitreal injection of amikacin in the treatment of endophthalmitis, and to provide reference for clinical decision making, registered (PROSPERO-CRD42022300395) and performed according PRISMA. PubMed, EMbase, The Cochrane Library, ClinicalTrials.gov, CNKI and Wanfang database were searched by computer to collect clinical studies on the efficacy and safety of intravitreal amikacin in the treatment of endophthalmitis. The retrieval period is from database construction to June 20, 2022. Two evaluators independently screened the literature according to the inclusion and exclusion criteria, extracted the data and evaluated the quality. Then qualitative analysis was used to describe the results. Finally, 5 case series studies were included, and the disease was exogenous endophthalmitis. A total of 115 patients and 115 eyes were included, with 11 to 39 patients in each study, 36.84% to 85.71% males and 30.4 to 60.7 years old on average. Follow-up was 6 weeks to 12 months. The study intervention of intravitreal vancomycin and amikacin improved visual acuity after combined therapy. In the 5 studies included in this study, no intraocular or systemic systemic adverse reactions were reported for intravitreal injection of amikacin. It was found that patients with exogenous endophthalmitis, including after surgery or ocular trauma, intravitreal injection of amikacin in combination with vancomycin is recommended for empiric treatment. However, high-quality randomized controlled trials or cohort studies are needed to verify this.","PeriodicalId":7147,"journal":{"name":"Acta poloniae pharmaceutica","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta poloniae pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32383/appdr/163452","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The aim of this study was to evaluate the efficacy and safety of intravitreal injection of amikacin in the treatment of endophthalmitis, and to provide reference for clinical decision making, registered (PROSPERO-CRD42022300395) and performed according PRISMA. PubMed, EMbase, The Cochrane Library, ClinicalTrials.gov, CNKI and Wanfang database were searched by computer to collect clinical studies on the efficacy and safety of intravitreal amikacin in the treatment of endophthalmitis. The retrieval period is from database construction to June 20, 2022. Two evaluators independently screened the literature according to the inclusion and exclusion criteria, extracted the data and evaluated the quality. Then qualitative analysis was used to describe the results. Finally, 5 case series studies were included, and the disease was exogenous endophthalmitis. A total of 115 patients and 115 eyes were included, with 11 to 39 patients in each study, 36.84% to 85.71% males and 30.4 to 60.7 years old on average. Follow-up was 6 weeks to 12 months. The study intervention of intravitreal vancomycin and amikacin improved visual acuity after combined therapy. In the 5 studies included in this study, no intraocular or systemic systemic adverse reactions were reported for intravitreal injection of amikacin. It was found that patients with exogenous endophthalmitis, including after surgery or ocular trauma, intravitreal injection of amikacin in combination with vancomycin is recommended for empiric treatment. However, high-quality randomized controlled trials or cohort studies are needed to verify this.
玻璃体内注射阿米卡星治疗眼内炎的疗效和安全性:一项系统综述
本研究的目的是评估玻璃体内注射阿米卡星治疗眼内炎的有效性和安全性,并为临床决策提供参考,注册(PROSPERO-CRD42022300395)并根据PRISMA进行。通过计算机检索PubMed、EMbase、The Cochrane Library、ClinicalTrials.gov、CNKI和万方数据库,收集玻璃体内阿米卡星治疗眼内炎的疗效和安全性的临床研究。检索期为数据库建设至2022年6月20日。两名评估人员根据纳入和排除标准对文献进行独立筛选,提取数据并评估质量。然后使用定性分析来描述结果。最后,纳入了5个病例系列研究,该疾病为外源性眼内炎。共纳入115名患者和115只眼睛,每个研究中有11至39名患者,36.84%至85.71%为男性,平均年龄30.4至60.7岁。随访时间为6周到12个月。玻璃体内万古霉素和阿米卡星的研究干预改善了联合治疗后的视力。在本研究的5项研究中,未报告玻璃体内注射阿米卡星的眼内或全身性不良反应。研究发现,外源性眼内炎患者,包括手术后或眼部创伤后,建议玻璃体内注射阿米卡星联合万古霉素进行经验性治疗。然而,需要高质量的随机对照试验或队列研究来验证这一点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
74
审稿时长
6-12 weeks
期刊介绍: The international journal of the Polish Pharmaceutical Society is published in 6 issues a year. The journal offers Open Access publication of original research papers, short communications and reviews written in English, in all areas of pharmaceutical sciences. The following areas of pharmaceutical sciences are covered: Analysis, Biopharmacy, Drug Biochemistry, Drug Synthesis, Natural Drugs, Pharmaceutical Technology, Pharmacology and General. A bimonthly appearing in English since 1994, which continues “Acta Poloniae Pharmaceutica”, whose first issue appeared in December 1937. The war halted the activity of the journal’s creators. Issuance of “Acta Poloniae Pharmaceutica” was resumed in 1947. From 1947 the journal appeared irregularly, initially as a quarterly, then a bimonthly. In the years 1963 – 1973 alongside the Polish version appeared the English edition of the journal. Starting from 1974 only works in English are published in the journal. Since 1995 the journal has been appearing very regularly in two-month intervals (six books a year). The journal publishes original works from all fields of pharmacy, summaries of postdoctoral dissertations and laboratory notes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信